Trial Profile
A Phase 1 Pharmacokinetic-pharmacodynamic Study Of Avelumab (msb0010718c) In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Hodgkin's disease
- Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Acronyms JAVELIN HODGKINS
- Sponsors Pfizer
- 09 Jun 2019 Status changed from active, no longer recruiting to discontinued.
- 15 Apr 2019 Planned End Date changed from 20 Aug 2021 to 1 Aug 2021.
- 15 Apr 2019 Planned primary completion date changed from 20 Aug 2020 to 1 Aug 2020.